<DOC>
	<DOC>NCT02840539</DOC>
	<brief_summary>The purpose of this study is to determine whether bortezomib, cytarabine, and dexamethasone are effective in the treatment of relapsed or refractory mantle cell lymphoma after 1 to 3 lines of previous treatment.</brief_summary>
	<brief_title>Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Pathologically confirmed mantle cell lymphoma Relapse or progression after 13 lines of previous chemotherapy with or without immunologic agents ECOG performance status 2 or less Adequate hematologic, hepatic, and renal function i. White blood cells ≥ 3,000 /ul ii. Absolute neutrophil count ≥ 1,000 /ul iii. Platelets ≥ 50,000 /ul iv. Hemoglobin ≥ 9.0 g/dL v. Total bilirubin &lt; 2 times upper limit of normal vi. AST, ALT &lt; 2.5 times upper limit of normal vii. Serum creatinine &lt; 1.5 times upper limit of normal Previously treated with 4 or more lines of chemotherapy with or without immunologic agents Previously treated with bortezomib Treated with a cytarabinecontaining regimen as the last line and within 6 months before registration Other cancer diagnosed within 5 years before registration Uncontrolled symptomatic CNS involvement of mantle cell lymphoma Uncontrolled systemic infection Inherited immunodeficiency disease or AIDS Pregnancy Breastfeeding Peripheral neuropathy of grade 3 or higher Other health conditions considered to be inappropriate for this trial in the primary physician's opinion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Mantle cell lymphoma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Cytarabine</keyword>
</DOC>